Aurobindo Pharma Subsidiary Completes 20% Equity Stake Dilution

• Rs 33.80 crore total consideration paid for 20% stake.
• 89,94,500 equity shares and 2,41,05,500 CCDs allotted to Dr. Rajendra Gadikota.

Reader Takeaway: Aurobindo retains 80% ownership and a future buyback option, signaling strategic continuity in the A1 Biochem integration.

What just happened

Aurobindo Pharma’s subsidiary, Apitoria Pharma, has concluded the allotment of equity shares and Compulsory Convertible Debentures (CCDs) to Dr. Rajendra Gadikota in A1 Biochem Labs (India) Private Limited. This move marks the formal transition of A1 Labs from a wholly-owned subsidiary to an 80% controlled entity within the Aurobindo Pharma group.

Transaction Details

The allotment involves 89,94,500 equity shares valued at Rs 9.18 crore and 2,41,05,500 CCDs valued at Rs 24.62 crore. The total consideration of Rs 33.80 crore aligns with the definitive agreements set during the initial acquisition of the A1 Biochem group. The subscription price was established through an independent valuation report from a Chartered Accountant.

Governance and Related Party Context

Dr. Rajendra Gadikota, a director at A1 Labs and former promoter of the A1 Biochem group, received the stake as part of the agreed-upon terms. The company maintains that the transaction was conducted at arm's length, having received necessary shareholder approval via a special resolution.

What changes now

While A1 Labs is no longer a wholly-owned subsidiary, it remains firmly under the Aurobindo Pharma umbrella. Crucially, Apitoria Pharma holds a contractual option to acquire this 20% stake back in the future, providing the company with flexibility to return to full ownership at a later stage.

Risks to watch

As with any related-party transactions, shareholders should monitor the long-term operational performance of A1 Labs to ensure it meets the internal value targets that justified its initial acquisition by the Aurobindo group.